Soul and Vibe Interactive, Inc. (SOUL) Reports Plan to Monetize Avatars for Marketing Impressions and Additional Revenues
Soul and Vibe Interactive, a publisher of games for consoles, mobile devices, and personal computers, today told investors that its business model includes selling monetized games-related content, including virtual apparel, costume, and prop collections for Avatars. In addition to generating an additional stream of revenue, Avatar items can promote brand awareness for Soul and Vibe’s games and intellectual properties.
Loans4Less.com, Inc. (LFLS) Launches New Marketing Initiative to Reach a Potential 1.7 Million
Loans4Less.com, an online mortgage loan brokerage firm focused on conforming loans, today announced the company is ramping up its brand exposure and market penetration by launching a targeted newspaper advertising campaign to a circulation of more than 1.7 million readers in California.
VentriPoint Diagnostics Ltd. (VPTDF) is “One to Watch”
VentriPoint Diagnostics leverages knowledge-based techniques to make heart analysis more convenient and less expensive. Having already installed multiple VMS™ analysis systems for heart testing in leading cardiac centers in Europe, Canada and the United States, the company is currently focused on expanding the applications of its technology beyond congenital heart disease in adults and children.
Bergamo Acquisition Corp. (BGMO) Solar Pumping System Does Heavy Lifting
It wasn’t that many years ago when solar power was hard to consider as a serious mainstream energy source, with what were then low-efficiency solar collectors and crude support technologies. Today, even though continuing technological breakthroughs and large scale installations have turned that impression around, there is still a sense that small remotely based solar PV systems are only good for powering low-consumption electronics, and that such systems are not yet ready to do any “heavy lifting.”
Scientific Reports Publishes International Stem Cell Corp. (ISCO) Technology for Deriving Neuronal Cell
International Stem Cell Corp., a biotechnology company focused on the therapeutic applications of human parthenogenetic stem cells (hpSC), this morning told investors that its breakthrough method of deriving neuronal cells for the treatment of Parkinson’s disease has been published in Scientific Reports, a primary research publication from the publishers of Nature Publishing Group.
International Stem Cell Corp. (ISCO) Investors Increase Stake in Company
International Stem Cell Corp., a California-based biotechnology company focused on the therapeutic applications of human parthenogenetic stem cells, announced today that $1 million has been invested by a number of existing long-standing investors through a private placement on the same terms as the transaction with management reported on January 22, 2013.
Viscount Systems, Inc. (VSYS) Secures Connecticut School with Freedom
“Like All Sleight-of-Hand Games It Cannot Continue Forever”
Spring is in the air, stock markets are driving higher than ever before, and happy days are here again.
Or are they?
Rainbow Coral Corp. (RBCC) to Participate in the Growing $60 Billion Drug Delivery Market
The next generation of advanced pharmaceutical technologies holds great potential and could fuel extraordinary growth in the $60 billion global drug delivery market. Rainbow Coral’s biotech subsidiary, Rainbow BioSciences, aims to be right in the middle of the action.
Advaxis, Inc. (ADXS) Recognized for Biotech Achievements; Nominated for “Best Early-Stage Vaccine Biotech” Award
Biotech small-cap Advaxis has been nominated for the Vaccine Industry Excellence (ViE) Award sponsored by Novartis Vaccines and Diagnostics. The ViE award recognizes companies and individuals that have demonstrated influential accomplishments and contributions to the vaccine industry within the prior 12 months.
Viscount Systems, Inc. (VSYS) to Enhance Control Platform and Expand System Capabilities with Government Support
Viscount Systems, a leading-edge, high technology supplier of security systems and software, today announced that it has received conditional funding of up to $150,000 from the National Research Council of Canada Industrial Research Assistance Program (IRAP).
IRAP support will be used to advance the development of Viscount’s Freedom access control platform and to expand system capabilities to a number of key areas, including mobile devices, preparing for U.S. Government full FICAM compliance, enhancing the Freedom Microsoft Active Directory platform, and enhanced encryption.
The Guitammer Company’s technology, sold under the ButtKicker brand name, is famous around the world for its remarkable ability to translate low-frequency sounds into tactile chair vibrations that can make a good viewing or listening experience an extraordinary one. It is now used by entertainment and theater companies such as IMAX, Disney, and AMC, as well as by famous musicians. A recent comment from a devoted Guitammer fan sums it up:
Advaxis, Inc. (ADXS) ADXS-cHER2 Immunotherapy Research Nets Penn One Health Award
Advaxis, a clinical-stage biotechnology company developing the next-generation of immunotherapies for cancer and infectious diseases, today announced that Dr. Nicola Mason, lead investigator of the Penn canine study, and Dr. Yvonne Paterson, scientific founder of Advaxis, have been given the inaugural University of Pennsylvania One Health Award for their research of Advaxis’ proprietary immunotherapy, ADXS-cHER2, for the treatment of canine osteosarcoma.
Cardium Therapeutics, Inc. (CXM) Focuses on Its Wound Care Tissue Engineering Technology, Excellagen
Nothing is more dangerous to a diabetic than developing skin or tissue ulcers which may, if left untreated, necessitate the amputation of a finger, a toe, or even an entire hand or foot.
These ulcers, the result of advanced diabetes or certain neuropathic conditions – in which wounds were left untreated – appear as a result of slowed circulation to extremities, a condition associated with both types of diabetes (i.e., Type I, an auto-immune disease, and Type II, which exhibits as high levels of sugar in the blood).